Organic Active Ingredients TRIZ Cases

A hydrophobic hyaluronic acid aggregate with an association promoter sustains drug levels and solubilizes poorly water-soluble actives without toxic solvents.

An oxygen scavenger in the package prevents dronabinol oxidation, enabling room-temperature storage with longer shelf life and fewer impurities.

Administering deoxythymidine and deoxycytidine helps rebalance nucleotide pools, rescue mitochondrial DNA copy number, and improve TK2 deficiency outcomes.

New anti-sickling compound classes restore red blood cell morphology and reduce cytotoxic effects where current sickle cell therapies fall short.

Controlled oral minoxidil release maintains therapeutic serum levels for hair loss while reducing adverse effects and frequent application.

pH-controlled coupling and cyclization steps produce stable, high-purity sGC stimulators and intermediates suitable for scale-up.

Using cacao bean shell as a ceramide source, this case shows how extraction yields ceramide AP-rich compositions for skin and hair moisturization.

Blocking CXCR4 and beta-adrenergic signaling with G-CSF improves stem cell and lymphocyte mobilization while reducing G-CSF burden.

Stable hydrogel bead controls mimic live, dead, and apoptotic cells to improve flow cytometry viability calibration with less time and waste.

A pyranopyridine scaffold improves CYP11B2 selectivity to lower aldosterone while minimizing CYP11B1 inhibition and cortisol-related side effects.

A polymer solid dispersion keeps amorphous psilocybin from crystallizing, enabling faster onset with shorter action and better shelf stability.

A cobalt(III) Schiff base complex addresses platinum-drug toxicity by inducing cancer cell cycle arrest while remaining less toxic to normal cells.

Ionizable lipid LNPs encapsulate capsid-free DNA to improve delivery while reducing liver toxicity and avoiding immune barriers to redosing.

Novel formula (I) compounds inhibit eIF4A helicase to block oncogenic mRNA translation and reduce tumor growth in dysproliferative diseases.

Controlled benzo[c]chroman salt polymorphs improve chemical stability and processability, reducing precipitation and agglomeration during scale-up.

Specific GOS and HMO blends boost microbiota GABA synthesis to help relieve stress and mood disorders in infants and children.

An mGlu5 negative allosteric modulator reduces Dravet syndrome seizure frequency and severity without the seizure worsening seen with some treatments.

Novel amide compounds broaden CSF-1R inhibition to other type III kinases, extending therapeutic use beyond limits seen with existing inhibitors.

Using disodium 5,10-methylene-(6R)-THF with citrate and sulfate enables a lyophilizate that preserves purity, solubility, and room-temperature stability.

Novel compounds selectively activate 5HT2A while limiting 5HT2B and 5HT2C activity, improving metabolic stability and reducing side effects.

A lipid-based amide anesthetic complex extends postsurgical analgesia with rapid onset while reducing toxicity and repeat dosing.

A plant-derived β-1,4 galactan adjuvant reprograms tumor-associated macrophages to boost checkpoint inhibitor efficacy in low-response tumors.

Combining a PDE9 inhibitor with serotonergic psychedelic drugs extends therapeutic benefits, reduces side effects, and lowers treatment burden.

Specific crystalline 4-PivO-NMT chloride forms enable precise molecular weight determination and more reliable dosage formulation.

Hydrophobic fat-coated active yeast and degradable binders enable gradual rumen release, supporting intake, health, and milk production.

High-dose lipid binding protein complexes lower inflammatory cytokines in sepsis, AKI, and cytokine release syndrome.

Losartan prevents checkpoint-blocker-induced brain edema in glioblastoma while preserving anti-tumor immunity through MT-MMP reduction.

A daily tafoxiparin regimen promotes cervical ripening and spontaneous term labor while avoiding invasive induction and prostaglandin-related side effects.

Periodic LVOT gradient and LVEF checks guide myosin inhibitor dosing to limit systolic dysfunction and heart failure risk.

Crystalline forms of a menin inhibitor block the menin-MLL interaction, reducing oncogene expression and promoting cell differentiation.

Multi-receptor gamma-carbolines target residual schizophrenia symptoms, including negative and cognitive impairments, beyond acute control.

Sustained iontophoretic co-delivery of NAD+ and peptides extends therapeutic action, bypasses first-pass metabolism, and supports wound repair.

Amino acid and sugar additives help PNA formulations improve solubility and stability while lowering dosage needs for nucleic acid modulation.

An anhydrous nirogacestat route uses CDI activation and pyridine hydrobromide buffering to limit impurities and preserve stereochemistry.

Blocking bile acid reabsorption with ASBT inhibitors lowers serum bile acids in cholestasis and improves pruritus and liver markers.

Novel tafamidis crystalline and amorphous forms improve processing, stability, dissolution, and bioavailability for amyloidosis treatment.

A biodegradable ocular implant releases axitinib over months to maintain retinal therapy while reducing repeat injections and systemic exposure.

MTAP deletion drives MTA buildup that enables selective PRMT5 inhibition in tumor cells, improving anti-tumor activity while limiting blood toxicity.

A fluorophore-labeled RNA cap preserves capping efficiency and mRNA stability while enabling cellular tracking for vaccine and drug research.

Genotype-guided HSD17B13 inhibition targets PNPLA3 I148M patients to reduce liver disease risk and mitigate liver injury.

Macrocyclic compounds target KRAS G12D, G12V, NRAS, and HRAS with strong inhibition, good druggability, and lower toxicity.

A multi-ingredient botanical mixture targets allergic and autoimmune inflammation while minimizing side effects and cytochrome P450 interactions.

Formula (I) compounds drive autophagy while concentrating in CNS tissue over peripheral sites, addressing selective treatment of neurological disease.

A boswellia, perilla, quercetin, and plant extract mixture targets allergic inflammation while avoiding cytochrome P450 drug interactions.

Salt conversion to a succinate form improves solubility, stability, and oral bioavailability while preserving CDK4/6 inhibitory activity.

Fused bicyclic heterocyclic compounds improve 15-PGDH inhibition through modular substituent design for treating related diseases.

Dual MEK and B-Raf inhibition improves tumor-growth control by blocking the MAPK pathway more effectively than monotherapy.

Biocompatible microspheres carry biofilm-forming probiotics and prebiotics to improve gut persistence, reduce inflammation, and support infant neurodevelopment.

This case uses sortilin-mediated peptide conjugates to increase drug uptake and address multidrug resistance in cancer therapy.

Borate/mannitol buffers stabilize concentrated articaine, enabling topical pars plana anesthesia and reducing procedure discomfort.

This composition replaces invasive HA delivery with baicalin and chlorogenic acid to stimulate endogenous skin synthesis.

This case uses an osmogent and inert-gas headspace to limit oxidation, keeping pemetrexed infusion solution stable for 24 months.

This case develops substituted piperidine-dione compounds to target AR signaling in resistant disease while limiting therapy side effects.

This case shows how Formula (I) compounds tune substituents to balance LRRK2 potency, selectivity, and blood-brain barrier penetration.

Fig-derived Lactobacillus paracasei targets IBD inflammation with cytokine suppression.

Attenuated bacteria deliver viral antigens to activate memory T cells for tumor control.

This case uses truncated coding elements and ribozyme recognition sites to produce accurate circRNA without added exon sequences.

Targeted SINEUP RNA enhances OPA1 translation to support mitochondrial function without disrupting protein isoform balance.

Leucine-assisted spray drying creates crystalline voriconazole powder with high drug content for deep-lung delivery.

This culture approach supports continuous keratinocyte expansion on a dermal structure, shortening culture time for large-area epithelium.

This case combines PD-1/PD-L1 checkpoint inhibition with a TLR agonist to relieve immune suppression and strengthen anti-tumor responses.

This case develops arylimidamide structures for anticancer activity with minimal toxicity to peripheral blood mononuclear cells.

This case uses benzimidazole carboxylic acids as oral GLP-1R agonists to support glucose control and weight management.

Controlled elution from an elastomeric device delivers local anesthetic to tissue while improving antimicrobial efficacy.

This case uses phenoxyazetidinyl pyrrolidine derivatives to activate GPR52, targeting psychosis while reducing D2-related side effects.

This case combines bupropion with dextromethorphan to sustain plasma levels and improve depression treatment in Asian patients.

Cathepsin-cleavable VAGGFG links Eribulin for controlled tumor-cell release, addressing linker complexity and off-target toxicity.

Novel polyketide compounds target tubulin and inhibit microtubule dynamics, addressing antitumor activity, toxicity, and pharmacokinetics.

This case uses alkyne compounds to inhibit Cathepsin K and limit bone resorption while addressing stroke risk linked to Odanacatib.

Side openings filter particles and concentrate embolic material for small-vessel delivery.

This case uses Formula I KDM5 inhibitors to maintain cancer treatment efficacy by targeting epigenetic mechanisms behind drug resistance.

This case uses solvates and unsolvated Form C to crystallize Formula I with long-term stability and low water vapor adsorption.

This case uses pH-controlled citrate or phosphate buffers to keep methotrexate dissolved and extend oral solution stability.

Modular PARP compounds use nuclear receptor binding to accumulate in tumor cells, improving tumor inhibition while sparing normal cells.

HEST uses factual questions, asterixis, symptoms, and coma status to standardize HE staging and guide treatment.

Carbamate prodrugs sustain exposure while reducing Parkinson’s treatment fluctuations.

This case targets acetaminophen-overdose liver injury by inhibiting HMGB1/RAGE signaling and reducing neutrophil infiltration.

A solid dispersion stabilizes amorphous abiraterone acetate to improve solubility, bioavailability, and absorption consistency.

Formula-based Cot modulators address limited therapeutic options while improving compound solubility and systemic exposure.

A 3:1 differential pressure controller keeps the flexible tube sealed until heat releases the sprinkler seal.

A sphingolipid, oil, and petrolatum-based ointment helps retain moisture and ease eyelid dryness, irritation, and itching.

Azaquinazoline compounds address limited KRas inhibitor coverage across multiple mutations.

Preconditioned MSCs improve survival, revascularization, and cardiac repair.

This case shows how PDE1 inhibition restores cAMP to limit inflammation, mitigate cytokine release syndrome, and enhance checkpoint therapy.

A controlled 90°C water extraction standardizes secoxyloganin-rich Lonicera japonica for antibacterial treatment of H. pylori.

Variable heterobicyclic amides selectively inhibit CD38, preventing NAD+ degradation and supporting immune function restoration.

Oxygen-scavenging additives prevent corticosteroid oxidation and preserve pH stability in aqueous eye drops for six months.

This dosage form combines a high molecular weight polyethylene oxide matrix with resistance to crushing and alcohol extraction.

This case shows how amide substitution and hydroxyl positioning improve resolvin stability, pharmacokinetics, and tissue repair.

This case uses BC1464 to interrupt FBXO7-mediated PINK1 degradation, reducing mitochondrial injury, cellular toxicity, and inflammation.

Cocultured neuronal and muscle cells form neuromuscular junctions for comparing disease models and screening drug combinations.

Bladder instillation delivers melatonin and antioxidants to the epithelium, bypassing first-pass metabolism to mitigate radiation injury.

This case combines iPSC-derived microglial co-cultures with CD11b agonists to enhance synaptic activity and rescue Rett-related defects.

A fixed-dose bilayer tablet combines dolutegravir and rilpivirine to reduce pill burden, interactions, and treatment complexity.

Selective sugar and linkage modifications improve adenosine-to-inosine editing while supporting stability and cellular uptake.

This case uses locally optimized, asymmetric heterocyclic compounds to target mutant KRAS G12D/G12V while limiting wild-type inhibition.

This case engineers VH/VL CDRs and cleavable linkers to improve B7-H3 binding specificity, conjugate stability, and tumor drug delivery.

This case combines HBV-targeting RNAi with anti-PDL1 antisense therapy to reduce HBsAg and HBV-DNA and support seroconversion.

Dissolving APIs in formic acid creates supersaturated solutions that improve manufacturing throughput and prevent nozzle clogging during spray drying.

Formula I heterocyclic compounds inhibit mutant EGFR and HER2 kinases, overcoming exon 20 insertion resistance for effective cancer treatment.

Co-spray drying ciprofloxacin with colistin prevents humidity-induced crystallization and maintains aerosolization performance.

Recombinant Bowman-Birk inhibitor protects oral therapeutic proteins from gastrointestinal degradation, ensuring sustained bioavailability.

Masitinib and gemcitabine combination therapy modulates tumor microenvironment mast cell activity to improve treatment outcomes.

Capsicum composition reduces oxidative stress and lactate levels while mitigating gastrointestinal discomfort during physical activity.

N-phenylalkyl amphetamine derivatives selectively inhibit VMAT2, reducing methamphetamine-stimulated locomotor activity and abuse potential.

Abiraterone decanoate prodrugs combined with lipid carriers resolve low oral bioavailability by enabling sustained therapeutic plasma levels.

Isotopic substitution of the thienopyridine core resolves pharmacokinetic limitations while maintaining high CDK8/19 specificity.

Modified mRNA vaccines target pathogenic soluble TNFR2 to stabilize atherosclerotic plaques.

Controlled crystallization of a KRAS G12C inhibitor yields stable crystal forms that resolve chemical instability and product aggregation issues.

Piperidinone carboxamide azaindane derivatives antagonize CGRP receptors, addressing the lack of potent receptor antagonists for treating migraine.

Foot electrical nerve stimulation inhibits bladder contractions, reducing urinary frequency and improving capacity without invasive surgery.

Modified betulinic acid compounds prevent HIV maturation, addressing drug resistance and incomplete viral suppression in current therapies.

Controlled Ziprasidone sulfate polymorphs resolve the purity versus solubility trade-off by optimizing crystal structure to improve bioavailability.

A dual carrier topical system uses dimethyl sulfoxide and dipropylene glycol to enhance tissue penetration of tetracycline.

Administering probiotics alongside chemotherapy modulates the gut microbiota to enhance anticancer immune responses and reduce treatment-related complications.

Isoflavonoid derivatives induce apoptosis in cancer cells and restore sensitivity to chemotherapeutic agents, countering treatment resistance.

PERK pathway inhibitors block unfolded protein response signaling to reduce alveolar overdistention and inflammation in acute respiratory distress syndrome.

Formula I compounds inhibit Src Homology-2 phosphatase activity, blocking aberrant signaling pathways to treat Noonan Syndrome and cancer.

Non-aqueous oral pharmaceutical solution comprising fludrocortisone acetate and medium-chain fatty acid triglycerides.

Riclinoctaose alleviates liver, kidney, and brain injury by reducing necrotic damage and enzyme activities during ischemia-reperfusion.

Combining afucosylated anti-CD19 antibodies with anti-CD20 agents overcomes resistance in diffuse large B cell lymphoma.

Solid state forms of (17-β)-hydroxy-4-androsten-3-one esters enhance oral bioavailability through optimized solubility profiles.

Adjusting digoxin doses based on serum levels prevents interaction risks while maintaining therapeutic efficacy.

Topical application of CRISPR-edited human-specific bacteria promotes beneficial microbial secretions to reduce infection susceptibility in aging skin.

Microcapsules shield capsaicin from oral tissues while releasing it in the gut to suppress hunger via TRPV1 receptor activation.

Stabilized cyanoacrylate monomers homogenously mixed with vitamin K oxide for wound healing applications.

Allele-specific microRNAs selectively inhibit mutant TMC1 transcripts while preserving wild-type function, halting progressive hearing loss.

Amorphous taxane solid dispersion in HPMCAS carrier overcomes low bioavailability and loading limits by maintaining supersaturated solubility.

Recombinant chimera polypeptides combine DNase I and Cdt fragments to inhibit neoplastic cell proliferation.

Recrystallizing the JAK inhibitor in methanol produces stable crystal form I, eliminating agglomeration and meeting pharmacopoeia purity limits.

Plasma cell-free nucleic acid analysis uses housekeeping gene normalization to confirm sample integrity before quantifying tumor-specific mutations.

Isolated tanshinones from Salvia miltiorrhiza lower seizure activity while minimizing side effects associated with conventional antiepileptic drugs.

Linking low-permeability compounds to DNA or RNA via a linker enables effective cellular uptake while preserving the therapeutic integrity of the active agent.

Mixing ionizable lipids with buffering agents creates stable lipid nanoparticles that improve intracellular delivery while reducing immunogenicity.

Heteroaryl derivatives target PKMYT1 and CCNE1 overactivation, resolving insufficient treatment responsiveness in existing chemotherapy regimens.

Segmented extraction and parameter standardization resolve the trade-off between process complexity and therapeutic efficacy in Withania somnifera formulations.

Formula I compounds overcome MCL-1 overexpression and drug resistance by inhibiting anti-apoptotic activity in various cancers.

Bivalent inhibitors link two bromodomain motifs to engage tandem binding sites, resolving low potency of monovalent compounds.

Thiosemicarbazone-iron complexes induce apoptosis in leukemia cells while sparing normal endothelial cells through localized structural modifications.

Bicyclic heterocycle derivatives inhibit protein kinase B while reducing toxicity and hERG blocking liability.

A targeted nutritional supplement formulation delivers specific vitamins and minerals to support maternal health.

Combining GLP1R agonists with metformin enhances glucose-dependent insulin secretion.